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Stage IV melanoma has historically had a poor prognosis
because of lack of responsiveness to traditional che-
motherapeutics. The 1-year survival rate of patients diag-
nosed with stage IV melanoma varies between 33 and
66%. Depending on the number, the location, and the
resectability of distant metastases, common treatment
options comprise surgery, systemic medical therapy, and
radiotherapy.
Single-agent DTIC has been the standard chemother-
apy regimen for metastatic melanoma since 1970s. From
a recent meta-analysis Luo et al [1] demonstrated that
the substantial benefit from any of the various combina-
tions of chemotherapy and biochemotherapy is about
4.2% with a mean overall survival of 6 months.
Patients who have limited sites of metastatic disease, a
long disease-free survival and a tumor doubling time
higher than 60 days, may be amenable to surgical resection
and complete surgical excision of limited metastatic dis-
ease can result in prolonged relapse-free survival in care-
fully selected patients. The potential for complete surgical
resection to benefit individual patients is suggested by the
results of a prospective, phase II study from the Southwest
Oncology Group. In this prospective, multicenter study,
64 of 77 carefully selected patients were able to undergo
complete resection of all sites of metastatic disease. Over-
all, the three and four-year survival rates were 36 and
31 percent, respectively, although late relapses continued
to be observed after this time.
Ipilimumab is a fully human monoclonal antibody
directed against cytotoxic T-lymphocyteassociated anti-
gen-4 (CTLA-4), a negative regulator of T-cell-mediated
immune responses. In Phase III trials, ipilimumab treat-
ment significantly extended overall survival (OS) com-
pared with control in both pretreated and treatment-
naϊve patients. Approximately 10% of patients present
objective responses by standard criteria, whereas
10–20% have stable disease or minor responses, that
translate into a clinical benefit. In patients who initially
achieve clinical benefit and then relapse months or years
later, re-treatment with ipilimumab can be also
advantageous.
Vemurafenib stands as the first personalized treatment
in melanoma based on a specific mutation, with a favor-
able impact on survival. The overall survival rate at
6 months was 77% and 58% at 12.
As a consequence, future improvements of this tar-
geted and personalized approaches are expected from
ongoing clinical trials aiming at potentiate the activity of
BRAF inhibitors through combination with other mole-
cules. These combination therapies also aim at lowering
the observed skin toxicities.
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